Gene therapy for chronic granulomatous disease.
Patients with chronic granulomatous disease (CGD) cannot generate reactive oxygen metabolites, and suffer from severe recurrent infections and dysregulated inflammation. Haematopoietic stem cell transplantation is the only established option for definitive cure for patients with a suitable donor and is indicated when conventional prophylaxis and therapy with antimicrobial medication fail. Gene therapy has the potential to cure CGD, and several clinical trials have been conducted since 1997. Whereas initial studies resulted in low and short-term engraftment of CGD-corrected cells, recent trials demonstrated clinical benefit when engraftment was enhanced by busulfan conditioning prior to infusion of gene-corrected cells. However, the progress in gene therapy has been hampered by the appearance of insertional mutagenesis causing leukaemia in a trial for patients with X-linked severe combined immunodeficiency and by the emergence of dominant clones in a recent trial for the X-linked form of CGD. These findings stimulated the development of modified vector systems that demonstrate reduced genotoxicity in vitro and in animal models. New gene therapy protocols that allow efficient gene transfer and durable expression but limit the risk for insertional mutagenesis are envisioned to become an important therapeutic option for patients with CGD.
University Clinic Carl Gustav Carus Dresden, Department of Pediatrics, Building 21, Fetscher Street 74 , 01307 Dresden, Germany.
Martin F
MF
Ryser
Joachim
J
Roesler
Marcus
M
Gentsch
Sebastian
S
Brenner
D000818:Animals; D002986:Clinical Trials as Topic; D004195:Disease Models, Animal; D015316:Genetic Therapy / Q000009:adverse effects / Q000379:methods / Q000639:trends; D006105:Granulomatous Disease, Chronic / Q000401:mortality / Q000503:physiopathology / Q000628:therapy*; D006801:Humans; D016254:Mutagenesis, Insertional / Q000379:methods*